At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4139 Biotechnology
Closed 11-22 16:00:00 EST
56.13
+0.91
+1.65%
High56.40Low55.22Vol599.50M
Open55.22D1 Closing55.21Amplitude2.14%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O11.86BT/O Rate--Tradable Shares0.00
P/B5.431127ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Apollomics Inc trading halted, news pending
TIPRANKS  ·  45 minutes ago
Apollomics Inc trading halted, news pending
US FDA approves BridgeBio's drug for rare heart condition
Reuters  ·  08:21
US FDA approves BridgeBio's drug for rare heart condition
BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients
Reuters  ·  08:18
BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
THOMSON REUTERS  ·  08:11
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm
THOMSON REUTERS  ·  08:11
BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe
THOMSON REUTERS  ·  08:11
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
THOMSON REUTERS  ·  08:11
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
GeneTether Therapeutics Reveals Q3 Results and New Drug Plans
TIPRANKS  ·  08:05
GeneTether Therapeutics Reveals Q3 Results and New Drug Plans
A Letter to Myself Podcast: A mother’s battle to overcome drug addiction fuelled by the fear of losing her children
CNA  ·  07:30
A Letter to Myself Podcast: A mother’s battle to overcome drug addiction fuelled by the fear of losing her children
Press Release: NEXTRAN TRUCK CENTERS ACQUIRES QUINCY MACK, DECATUR MACK, AND H&L MACK
Dow Jones  ·  06:24
Press Release: NEXTRAN TRUCK CENTERS ACQUIRES QUINCY MACK, DECATUR MACK, AND H&L MACK
BRIEF-Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Reuters  ·  06:23
BRIEF-Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Ocean Biomedical Faces Nasdaq Delisting Threat
TIPRANKS  ·  06:20
Ocean Biomedical Faces Nasdaq Delisting Threat
Mustang Bio files to sell 34.77M shares of common stock for holders
seekingalpha  ·  05:56
Mustang Bio files to sell 34.77M shares of common stock for holders
Top Research Reports for GE Aerospace, Fomento Economico & Waste Management
Zacks  ·  05:56
Top Research Reports for GE Aerospace, Fomento Economico & Waste Management
BRIEF-Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq Compliance
Reuters  ·  05:55
BRIEF-Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq Compliance
Ocean Biomedical receives notice from Nasdaq regarding late filing
seekingalpha  ·  05:53
Ocean Biomedical receives notice from Nasdaq regarding late filing
Amarin Corp - Nasdaq Granted 180 Days to Regain Nasdaq Compliance
THOMSON REUTERS  ·  05:52
Amarin Corp - Nasdaq Granted 180 Days to Regain Nasdaq Compliance
Immunome Files Prospectus for Stock Offering By Selling Shareholders
MT Newswires Live  ·  05:52
Immunome Files Prospectus for Stock Offering By Selling Shareholders
BRIEF-Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q
Reuters  ·  05:45
BRIEF-Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q
Ocean Biomedical, Inc. Announces Receipt of Notice From Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
THOMSON REUTERS  ·  05:45
Ocean Biomedical, Inc. Announces Receipt of Notice From Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Introduction

Company Name.
BK4139
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--